EQS-News

PAION AG publishes GROUP QUARTERLY STATEMENT for the first quarter of 2023

EQS-News: PAION AG / Key word(s): Quarterly / Interim Statement PAION AG publishes GROUP QUARTERLY STATEMENT for the first quarter of 2023 17.05.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG publishes GROUP QUARTERLY STATEMENT for the first quarter of 2023

 

• EU marketing authorization for remimazolam in general anesthesia in April 2023 opens up new growth opportunities
• Capital reduction implemented in the first quarter of 2023
• Initiatives to expand commercial sales continued
• Sales revenues in the amount of EUR 2.3 million.
• Cash and cash equivalents of EUR 7.2 million as of March 31, 2023
• Q1 2023 Webcast (English) today at 2:00 p.m. CEST (1:00 p.m. BST/8:00 a.m. EDT)

 

Aachen (Germany), May 17, 2023 - The specialty pharmaceutical company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8K) today reports its consolidated financial results according to International Financial Reporting Standards (IFRS) for the first quarter of 2023.

Gregor Siebert, CEO of PAION AG, commented: "At the beginning of April 2023, we were able to reach an important milestone in the company's history. Our lead compound remimazolam was approved for general anesthesia and opens up new growth opportunities for PAION. Currently, preparations are underway for the marketing launch in Europe, which we have planned for the beginning of the second half of 2023. Thus, we continued the commercialization of our products in the first quarter of 2023 and will launch them in additional European countries to offer innovative treatment options for the still unmet and growing medical need in anesthesia and intensive care.”

 

Business performance in the first three months of 2023

PAION continued to expand its commercialization infrastructure for the marketing activities in selected target markets in the first quarter of 2023, including the necessary production, supply and distribution structures as well as the marketing and sales processes for the entire product portfolio.